ReNeuron Group PLC

ReNeuron Group PLC

ReNeuron Group PLC

Overview
Date Founded

2005

Headquarters

Pencoed Business Park,Pencoed, Bridgend CF35 5HY

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. It develops its core stem cell assets such as CTX neural cell line and human retinal progenitor cells. The company was founded by John David Sinden in 1997 and is headquartered in Pencoed, the United Kingdom.

In The News
Executives & Employees

Chief Financial Officer, Secretary & Executive Director

Executive Director, Chief Executive Officer

Chief Medical Officer

Chief Medical Officer

Head of Research

Vice President-Regulatory Affairs & Pharmacovigilance

Vice President, Business Development & Alliance Management

Board of Directors

Non-Executive Director, Head-Clinical & Regulatory at Circassia Ltd.

Founder at Merlin Entertainments Group Operations Ltd.

Executive Director, Chief Executive Officer at ReNeuron Group PLC

Chief Financial Officer, Secretary & Executive Director at ReNeuron Group PLC

Chief Executive Officer & Director at Glialign Ltd.

Former Partner at Taube Hodson Stonex Partners LLP

Paths to ReNeuron Group PLC
Potential Connections via
Relationship Science
You
ReNeuron Group PLC
Owners & Shareholders
Details Hidden

Woodford is an active, long-term manager which follows a patient capital investment style, focusing on absolute risk and aiming to provide positive long-term returns. They are first and foremost stock pickers and combine rigorous fundamental analysis of companies with their perspective of the long-term macroeconomic outlook and variables and how these might impact existing or potential holdings. The firm constructs investment rationales and makes informed decisions, seeking to add value through the investment process. They invest in a larger number of smaller positions, aiming to achieve capital preservation through diversification. Woodford focuses on value discovery and believe that by focusing on valuation and identifying companies that can deliver sustainable growth they can deliver great long-term outcomes. They make investment decisions that balance macro views, business specifics and the firm’s view on management teams, seeking to invest in well-run, high-quality businesses.

Details Hidden

Partners Investment Co. LLP is a private company headquartered in London, UK. The firm provides investment advice. It was founded in 2017 by Magnus Edward Spence-Jones.

Recent Transactions
Details Hidden

ReNeuron Group PLC issued GBP Ordinary Shares

Details Hidden

ReNeuron Group PLC issued Up to GBP Ordinary Shares

Details Hidden

ReNeuron Group PLC issued GBP Ordinary Shares

Transaction Advisors
Investment Advisor

Advised onReNeuron Group PLC issued GBP Ordinary Shares

Broker

Advised onReNeuron Group PLC issued GBP Ordinary Shares

Auditor

Advised onReNeuron Group PLC issued Up to GBP Ordinary Shares

Professional

Advised onReNeuron Group PLC issued GBP Ordinary Shares

Investment Advisor

Advised onReNeuron Group PLC issued GBP Ordinary Shares

Investment Advisor

Advised onReNeuron Group PLC issued GBP Ordinary Shares

Clients

Shanghai Fosun Pharmaceutical Group Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products and medical equipment, import and export of medical equipment, healthcare services, and the provision of related and other consulting services and investment management. It operates through the following business segment: Pharmaceutical Manufacturing and R&D; Healthcare Service; Medical Devices and Medical Diagnosis; Pharmaceutical Distribution and Retail; and Other Business Operations. The Pharmaceutical Manufacturing and R&D segment involves in the production, sale, and research of medicine. The Healthcare Service segment provides healthcare service and hospital management. The Medical Devices and Medical Diagnosis segment focuses on the production and sale of medical equipment and diagnostic products. The Pharmaceutical Distribution and Retail segment issue retail and wholesale of medicine. The Other Business Operations segment comprises business that is different from the role of other segments. The company was founded on January 14, 1994 and is headquartered in Shanghai, China.

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate & Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Key Stats and Financials As of 2020
Market Capitalization
$91.6M
Total Enterprise Value
$24.5M
Earnings Per Share
$-0.43
Total Equity
$16.4M
Total Debt
$1.08M
EBITDA
$-17.5M
Net Profit
$-14.1M
Revenue
$7.52M
Debt TEV
0.04x
TEVNet Income
-1.73x
Enterprise Value / Sales
3.26x
EBITDAMargin
-232.43%
Three Year Compounded Annual Growth Rate Of Revenue
408.96%
Competitors
Biogen, Inc. Biotechnology - Canyon Country, CA

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Meiragtx Holdings Plc Biotechnology - New York, NY

MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ReNeuron Group PLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ReNeuron Group PLC's profile does not indicate a business or promotional relationship of any kind between RelSci and ReNeuron Group PLC.